Antidepressant Trial Duration Versus Duration of Real-World Use: A Systematic Analysis

Antidepressant use is rising globally, with increasing duration of real-world prescribing. While the FDA considers 6-8 week trials adequate for regulatory approval, guidelines recommend prolonged treatment, raising questions about evidence supporting long-term prescribing practices.

This descriptive review analyzed 52 placebo-controlled randomized trials (n = 10,116) of the 10 most commonly prescribed antidepressants, sampled at 5-year intervals (1978-2023). We compared trial durations with real-world usage patterns from the National Health and Nutrition Examination Survey and assessed methodological characteristics including standardized scales, withdrawal monitoring, and taper protocols.

The median duration of antidepressant use in the United States was approximately 5 years, while the median trial duration was 8 weeks (IQR: 6-12 weeks). Among trials, 88.5% (n = 46) lasted ≤12 weeks, 11.5% (n = 6) randomized participants beyond 12 weeks, and none exceeded 52 weeks. Few trials monitored withdrawal symptoms (3.8%), included taper protocols (18.9%), or reported post-treatment outcomes (1.9%).

A substantial discordance exists between the typical 8-week duration of clinical trials and the median 5-year real-world use of antidepressants. This gap, compounded by inadequate monitoring for withdrawal effects and post-treatment outcomes, raises important questions about the evidence supporting current long-term prescribing practices. Publicly funded trials of longer duration that include monitoring for withdrawal and relapse are necessary to determine optimal antidepressant therapy duration.